[引用][C] A guideline for discussion and some thoughts.
MJ Droller - The Journal of urology, 2009 - europepmc.org
A guideline for discussion and some thoughts. - Abstract - Europe PMC Sign in | Create an
account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk …
account https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk …
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials …
O Cussenot, AR Azzouzi, N Nicolaiew, P Mangin… - European urology, 2007 - Elsevier
OBJECTIVE: The 5-alpha-reductase type 2 (5A2) enzyme catalyses the irreversible
conversion of testosterone to dihydrotestosterone, the most active androgen in the prostate …
conversion of testosterone to dihydrotestosterone, the most active androgen in the prostate …
Variability in the androgen response of prostate epithelium to 5α-reductase inhibition: implications for prostate cancer chemoprevention
EA Mostaghel, L Geng, I Holcomb, IM Coleman… - Cancer research, 2010 - AACR
Inhibitors of 5α-reductase (SRD5A) that lower intraprostatic levels of dihydrotestosterone
(DHT) reduce the overall incidence of prostate cancer (PCa), but there is significant variation …
(DHT) reduce the overall incidence of prostate cancer (PCa), but there is significant variation …
5α-Reductase 2 polymorphisms as risk factors in prostate cancer
T Söderström, M Wadelius, SO Andersson… - Pharmacogenetics …, 2002 - journals.lww.com
Prostate cancer is a significant cause of death in Western countries and is under the strong
influence of androgens. The steroid 5α-reductase 2 catalyzes the metabolism of testosterone …
influence of androgens. The steroid 5α-reductase 2 catalyzes the metabolism of testosterone …
SRD5A1 and SRD5A2 are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-Reductase Inhibitors and α-Adrenergic Receptor …
Purpose: Common treatments for benign prostatic hyperplasia include 5α-reductase
inhibitors and α-adrenergic receptor antagonists. However, these treatments can only …
inhibitors and α-adrenergic receptor antagonists. However, these treatments can only …
The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer
JK Scariano, E Treat, F Alba, H Nelson, SA Ness… - The …, 2008 - Wiley Online Library
BACKGROUND Emerging evidence indicates that testosterone (T), and not
dihydrotestosterone (DHT), is the most relevant androgen that promotes carcinogenesis in …
dihydrotestosterone (DHT), is the most relevant androgen that promotes carcinogenesis in …
Polymorphic Markers in the SRD5A2 Gene and Prostate Cancer Risk: A Population-based Case-control Study
AW Hsing, C Chen, AP Chokkalingam, YT Gao… - … Biomarkers & Prevention, 2001 - AACR
It has been suggested that the activity of the steroid 5α-reductase type II enzyme (encoded
by the SRD5A2 gene) may be associated with prostate cancer risk and that population …
by the SRD5A2 gene) may be associated with prostate cancer risk and that population …
The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer
Abstract 5α-Reductase type 2, the predominant prostatic isozyme of this protein, converts
testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater …
testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater …
MP81-16 METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN …
T Deng, X Lin, S Wu, Z Zhang, CL Wu, L Yan… - The Journal of …, 2019 - auajournals.org
INTRODUCTION AND OBJECTIVES: Steroid 5-alpha reductase (SRD5A2) is a critical
enzyme for prostatic development and growth. We have found that epigenetic modifications …
enzyme for prostatic development and growth. We have found that epigenetic modifications …
SRD5A2 V89L polymorphism and prostate cancer risk: A meta‐analysis
C Wang, W Tao, Q Chen, H Hu, XY Wen, R Han - The Prostate, 2010 - Wiley Online Library
BACKGROUND Increasing studies investigating the association between steroid 5‐alpha
reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to …
reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to …